Abstract | BACKGROUND: METHODS: Sixteen volunteers with advanced prostate carcinoma submitted to pharmacological ADT or orchiectomy had plasma collected shortly before and after 6 months of ADT. In vitro transfer of lipids to HDL was performed by incubating plasma with donor emulsion containing radioactive lipids by 1 h at 37 °C. After chemical precipitation of apolipoprotein B-containing lipoprotein, the radioactivity of HDL fraction was counted. RESULTS: ADT reduced testosterone to nearly undetectable levels and markedly diminished PSA. ADT increased the body weight but glycemia, triglycerides, LDL and HDL cholesterol, HDL lipid composition and CETP concentration were unchanged. However, ADT increased the plasma unesterified cholesterol concentration (48 ± 12 vs 56 ± 12 mg/dL, p = 0.019) and LCAT concentration (7.15 ± 1.81 vs 8.01 ± 1.55μg/mL, p = 0.020). Transfer of unesterified (7.32 ± 1.09 vs 8.18 ± 1.52%, p < 0.05) and esterified cholesterol (6.15 ± 0.69 vs 6.94 ± 1.29%, p < 0.01) and of triglycerides (6.37 ± 0.43 vs 7.18 ± 0.91%, p < 0.001) to HDL were increased after ADT. Phospholipid transfer was unchanged. CONCLUSION: Increase in transfer of unesterified and esterified cholesterol protects against cardiovascular disease, as shown previously, and increased LCAT favors cholesterol esterification and facilitates the reverse cholesterol transport. Thus, our results suggest that ADT may offer anti- atherosclerosis protection by improving HDL functional properties. This could counteract, at least partially, the eventual worse effects on plasma lipids.
|
Authors | Cicero P Albuquerque, Fatima R Freitas, Ana Elisa M Martinelli, Josefa H Lima, Rafael F Coelho, Carlos V Serrano Jr, Willian C Nahas, Roberto Kalil Filho, Raul C Maranhão |
Journal | Lipids in health and disease
(Lipids Health Dis)
Vol. 19
Issue 1
Pg. 133
(Jun 10 2020)
ISSN: 1476-511X [Electronic] England |
PMID | 32522195
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Cholesterol Esters
- Lipids
- Lipoproteins, HDL
- Phospholipids
- Triglycerides
- Goserelin
- Testosterone
- Cholesterol
- KLK3 protein, human
- Kallikreins
- Prostate-Specific Antigen
|
Topics |
- Aged
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Atherosclerosis
(prevention & control)
- Cholesterol
(blood)
- Cholesterol Esters
(blood)
- Goserelin
(therapeutic use)
- Humans
- Kallikreins
(blood)
- Lipids
(blood)
- Lipoproteins, HDL
(blood)
- Male
- Middle Aged
- Orchiectomy
- Phospholipids
(blood)
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(blood, therapy)
- Testosterone
(blood)
- Triglycerides
(blood)
|